JP2014511840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511840A5 JP2014511840A5 JP2014501220A JP2014501220A JP2014511840A5 JP 2014511840 A5 JP2014511840 A5 JP 2014511840A5 JP 2014501220 A JP2014501220 A JP 2014501220A JP 2014501220 A JP2014501220 A JP 2014501220A JP 2014511840 A5 JP2014511840 A5 JP 2014511840A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- oxo
- phenyl
- trifluoropropyl
- succinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BDBIBRDNIFFYLE-UHFFFAOYSA-N n'-(3,3,3-trifluoropropyl)butanediamide Chemical compound NC(=O)CCC(=O)NCCC(F)(F)F BDBIBRDNIFFYLE-UHFFFAOYSA-N 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- -1 3,3,3-trifluoropropyl Chemical group 0.000 claims 3
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- CZRZGKHVNFKAIZ-UHFFFAOYSA-N C(CCC(=O)N)(=O)NCCCF Chemical compound C(CCC(=O)N)(=O)NCCCF CZRZGKHVNFKAIZ-UHFFFAOYSA-N 0.000 claims 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229960002448 dasatinib Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000004088 simulation Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 0 *[C@@]([C@@](*)C(N[C@]1N=C(c2ccccc2)c(cccc2)c2N(*)C1=O)=O)C(N)=O Chemical compound *[C@@]([C@@](*)C(N[C@]1N=C(c2ccccc2)c(cccc2)c2N(*)C1=O)=O)C(N)=O 0.000 description 2
- AYOUDDAETNMCBW-GSHUGGBRSA-N CN(c(cccc1)c1C(c1ccccc1)=N[C@@H]1NC([C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)=O)C1=O Chemical compound CN(c(cccc1)c1C(c1ccccc1)=N[C@@H]1NC([C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)=O)C1=O AYOUDDAETNMCBW-GSHUGGBRSA-N 0.000 description 2
- WJEXAUOGHKSGBR-GCKMJXCFSA-N NC([C@@H](CCC(F)(F)F)[C@@H](CCC(F)(F)F)C(N[C@H]1N=C(c2ccccc2)c(cccc2)c2NC1=O)=O)=O Chemical compound NC([C@@H](CCC(F)(F)F)[C@@H](CCC(F)(F)F)C(N[C@H]1N=C(c2ccccc2)c(cccc2)c2NC1=O)=O)=O WJEXAUOGHKSGBR-GCKMJXCFSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466238P | 2011-03-22 | 2011-03-22 | |
| US61/466,238 | 2011-03-22 | ||
| PCT/US2012/030021 WO2012129353A1 (en) | 2011-03-22 | 2012-03-22 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511840A JP2014511840A (ja) | 2014-05-19 |
| JP2014511840A5 true JP2014511840A5 (enExample) | 2014-07-31 |
| JP5873923B2 JP5873923B2 (ja) | 2016-03-01 |
Family
ID=45894701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501220A Active JP5873923B2 (ja) | 2011-03-22 | 2012-03-22 | ビス（フルオロアルキル）−１，４−ベンゾジアゼピノン化合物 |
Country Status (32)
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| JP6170496B2 (ja) | 2011-09-23 | 2017-07-26 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用 |
| JP2015533811A (ja) | 2012-09-21 | 2015-11-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物 |
| CN104854094A (zh) * | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | 氟烷基二苯并二氮杂*酮化合物 |
| WO2014047397A1 (en) * | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
| EP2897947B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| CN104822677A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
| US9273075B2 (en) | 2012-09-21 | 2016-03-01 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| US9249157B2 (en) | 2012-09-21 | 2016-02-02 | Bristol-Myers Squibb Company | Tricyclic heterocycle compounds |
| JP6371294B2 (ja) | 2012-10-31 | 2018-08-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング |
| US9492469B2 (en) | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| CN103435562B (zh) * | 2013-08-26 | 2016-02-24 | 华东理工大学 | 6-取代苯并二氮卓-2,4-二酮类化合物及其用途 |
| US10174015B2 (en) | 2014-10-31 | 2019-01-08 | Xiamen University | Substituted heterocyclic derivative, preparation method and use thereof |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CN104352488B (zh) * | 2014-10-31 | 2016-08-31 | 厦门大学 | 一类取代杂环衍生物在制备治疗疼痛药物中的应用 |
| CN104356082B (zh) * | 2014-10-31 | 2016-07-13 | 厦门大学 | 一类取代杂环衍生物及其制备方法 |
| CN104892532B (zh) * | 2015-05-20 | 2017-09-08 | 成都理工大学 | 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺 |
| AU2016297024B2 (en) | 2015-07-22 | 2021-03-04 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as RSV inhibitors |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| EP3402799B1 (en) | 2016-01-15 | 2022-05-04 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| AU2018221820B2 (en) | 2017-02-16 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| ES2817910T3 (es) * | 2017-08-04 | 2021-04-08 | Alzheimur 2012 S L | Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer |
| WO2019067864A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
| KR102845789B1 (ko) | 2017-11-01 | 2025-08-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| US12193994B2 (en) | 2017-11-06 | 2025-01-14 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| MX394621B (es) * | 2017-11-13 | 2025-03-24 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona |
| WO2019094920A1 (en) | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as rsv inhibitors |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| AU2019266150A1 (en) * | 2018-05-06 | 2021-01-07 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
| WO2019215585A1 (en) * | 2018-05-06 | 2019-11-14 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| CN112236147A (zh) * | 2018-05-15 | 2021-01-15 | 百时美施贵宝公司 | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法 |
| WO2019222231A1 (en) | 2018-05-15 | 2019-11-21 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |
| KR20210013184A (ko) * | 2018-05-24 | 2021-02-03 | 아얄라 파마큐티컬즈 아이엔씨. | 비스플루오로알킬-1,4-벤조디아제피논 화합물과 면역요법제를 포함하는 조성물 및 이의 사용 방법 |
| KR20250151605A (ko) | 2018-06-01 | 2025-10-21 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| JP7558189B2 (ja) | 2019-03-18 | 2024-09-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体 |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| CN113939297A (zh) * | 2019-05-15 | 2022-01-14 | 艾雅拉制药公司 | 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物 |
| AU2020307471A1 (en) | 2019-06-24 | 2022-01-27 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen |
| CA3153297A1 (en) | 2019-10-04 | 2021-04-08 | Adam SZYMANIAK | Antiviral heterocyclic compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| MX2023002612A (es) | 2020-09-03 | 2023-05-16 | Bristol Myers Squibb Co | Polimorfos de compuestos de bis(fluoroalquilo)-1,4-benzodiazepinon a y usos de los mismos. |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| WO2022122667A1 (en) | 2020-12-07 | 2022-06-16 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| WO2022182861A1 (en) | 2021-02-26 | 2022-09-01 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| CN117794536A (zh) | 2021-06-02 | 2024-03-29 | 塞莱斯蒂亚生物技术股份公司 | 在治疗自身免疫性和炎症性疾病的方法中使用的化合物 |
| EP4429661A1 (en) | 2021-11-08 | 2024-09-18 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| CN120882691A (zh) * | 2022-12-28 | 2025-10-31 | 伊米若梅有限公司 | 用于制备双(氟烷基)苯并二氮杂䓬酮化合物的中间体盐 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
| AU2555997A (en) * | 1996-04-03 | 1997-10-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| NZ509241A (en) | 1998-08-07 | 2003-08-29 | Du Pont Pharm Co | Succinoylamino lactams as inhibitors of alpha-beta protein production |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| CA2346099A1 (en) | 1998-11-12 | 2000-05-18 | Dupont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
| JP4615727B2 (ja) | 1998-12-24 | 2011-01-19 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Ａβタンパク質生成の阻害剤としてのスクシノイルアミノベンゾジアゼピン |
| IL146222A0 (en) | 1999-04-30 | 2002-07-25 | Univ Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
| US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
| US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
| EP1222176A1 (en) | 1999-10-08 | 2002-07-17 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
| NZ519984A (en) * | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| AU779875B2 (en) | 2000-01-24 | 2005-02-17 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
| US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
| CA2404314A1 (en) | 2000-03-31 | 2001-10-11 | Lorin Andrew Thompson | Succinoylamino heterocycles as inhibitors of a.beta. protein production |
| MXPA02009729A (es) | 2000-04-03 | 2003-03-27 | Bristol Myers Squibb Pharma Co | Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta. |
| AU2001253090A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of abeta protein production |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| US6632812B2 (en) | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
| AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| CA2379445C (en) | 2000-06-01 | 2007-08-21 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production |
| US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
| MXPA05002871A (es) | 2002-09-20 | 2005-10-05 | Arrow Therapeutics Ltd | Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen. |
| HRP20050663A2 (en) | 2003-02-04 | 2006-12-31 | F. Hoffmann - La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
| GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| AU2004270361B2 (en) | 2003-09-09 | 2009-06-25 | F. Hoffmann-La Roche Ag | Malonamide derivatives blocking the activity of gama-secretase |
| EP1795198A1 (en) | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Treatment of Barret's esophagus |
| US20080058316A1 (en) | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| KR101169628B1 (ko) | 2006-03-27 | 2012-07-30 | 에프. 호프만-라 로슈 아게 | 감마 세크레테아제 저해제로서의 말론아미드 유도체 |
| CA2663240A1 (en) | 2006-09-20 | 2008-03-27 | F. Hoffmann-La Roche Ag | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
| BRPI0815135A2 (pt) | 2007-08-14 | 2015-02-03 | Lilly Co Eli | Derivados de azepina como inibidores de gama secretase. |
| KR20100101624A (ko) | 2008-01-11 | 2010-09-17 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 감마-세크레타제 저해제의 용도 |
| WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
| US20120225860A1 (en) | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
-
2012
- 2012-02-24 TW TW101106426A patent/TWI530489B/zh active
- 2012-03-21 UY UY0001033961A patent/UY33961A/es active IP Right Grant
- 2012-03-21 AR ARP120100932A patent/AR085471A1/es not_active Application Discontinuation
- 2012-03-22 EA EA201391324A patent/EA022530B1/ru not_active IP Right Cessation
- 2012-03-22 CA CA2830902A patent/CA2830902C/en active Active
- 2012-03-22 PT PT127111029T patent/PT2688873E/pt unknown
- 2012-03-22 PL PL12711102T patent/PL2688873T3/pl unknown
- 2012-03-22 SG SG2013070743A patent/SG193555A1/en unknown
- 2012-03-22 KR KR1020137027347A patent/KR101948347B1/ko active Active
- 2012-03-22 ES ES12711102.9T patent/ES2534080T3/es active Active
- 2012-03-22 CN CN201280025022.2A patent/CN103717576B/zh active Active
- 2012-03-22 AU AU2012230904A patent/AU2012230904B2/en active Active
- 2012-03-22 MA MA36323A patent/MA35036B1/fr unknown
- 2012-03-22 WO PCT/US2012/030021 patent/WO2012129353A1/en not_active Ceased
- 2012-03-22 PE PE2013002083A patent/PE20140626A1/es active IP Right Grant
- 2012-03-22 HR HRP20150273TT patent/HRP20150273T1/hr unknown
- 2012-03-22 US US13/426,730 patent/US8629136B2/en active Active
- 2012-03-22 DK DK12711102T patent/DK2688873T3/en active
- 2012-03-22 RS RS20150150A patent/RS53843B1/sr unknown
- 2012-03-22 EP EP12711102.9A patent/EP2688873B1/en active Active
- 2012-03-22 JP JP2014501220A patent/JP5873923B2/ja active Active
- 2012-03-22 PH PH1/2013/501738A patent/PH12013501738B1/en unknown
- 2012-03-22 SI SI201230162T patent/SI2688873T1/sl unknown
- 2012-03-22 MY MYPI2013003410A patent/MY161233A/en unknown
- 2012-03-22 BR BR112013024059-8A patent/BR112013024059B1/pt active IP Right Grant
- 2012-03-22 MX MX2013010420A patent/MX2013010420A/es active IP Right Grant
-
2013
- 2013-09-17 IL IL228534A patent/IL228534A/en active IP Right Grant
- 2013-09-17 CL CL2013002690A patent/CL2013002690A1/es unknown
- 2013-09-19 TN TNP2013000372A patent/TN2013000372A1/fr unknown
- 2013-09-20 CO CO13224494A patent/CO6771446A2/es unknown
- 2013-12-09 US US14/100,896 patent/US8822454B2/en active Active
-
2015
- 2015-04-13 SM SM201500091T patent/SMT201500091B/xx unknown
- 2015-04-17 CY CY20151100355T patent/CY1116423T1/el unknown
-
2023
- 2023-07-07 AR ARP230101776A patent/AR129859A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511840A5 (enExample) | ||
| HRP20150273T1 (hr) | Spojevi bis(floroalkil)-1,4-benzodiazepinona | |
| JP7064772B2 (ja) | 選択的エストロゲン受容体ダウンレギュレーター（ｓｅｒｄｓ） | |
| JP2014507421A5 (enExample) | ||
| JP2018115191A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| RU2014102773A (ru) | Новые кристаллические формы ингибиторов дипептидилпептидазы-iv | |
| JP2013010792A5 (enExample) | ||
| JP2014518266A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2013505946A5 (enExample) | ||
| JP2011529054A5 (enExample) | ||
| JP2013545785A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP6014142B2 (ja) | Ｎ−ヒドロキシ−４−｛２−［３−（ｎ，ｎ−ジメチルアミノメチル）ベンゾフラン−２−イルカルボニルアミノ］エトキシ｝ベンズアミドの投与に関するスキーム | |
| HRP20160044T1 (hr) | Novi spojevi fenilamino izonikotinamida | |
| JP2020536893A5 (enExample) | ||
| JP2014530818A5 (enExample) |